{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T09:51:13Z","timestamp":1781344273743,"version":"3.54.1"},"reference-count":22,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IRDR"],"published-print":{"date-parts":[[2023,11,30]]},"DOI":"10.5582\/irdr.2023.01055","type":"journal-article","created":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T22:11:00Z","timestamp":1700345460000},"page":"257-261","source":"Crossref","is-referenced-by-count":13,"title":["Vosoritide, a miracle drug, covering unmet need in achondroplasia: A regulatory update"],"prefix":"10.5582","volume":"12","author":[{"family":"Simran","sequence":"first","affiliation":[{"name":"Department of Regulatory Affairs, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S S Kirthiga","family":"Devi","sequence":"additional","affiliation":[{"name":"Department of Regulatory Affairs, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabanis","family":"Chetan Dushantrao","sequence":"additional","affiliation":[{"name":"Department of Regulatory Affairs, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Joga","sequence":"additional","affiliation":[{"name":"Department of Regulatory Affairs, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Regulatory Affairs, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","unstructured":"1. Ministry of Health and Family Welfare. National policy for rare diseases, 2021. <i>https:\/\/main.mohfw.gov.in\/sites\/default\/files\/Final%20NPRD%2C%202021.pdf<\/i> (accessd February 11, 2023)."},{"key":"2","unstructured":"2. National Institute of Health. Achondroplasia. <i>https:\/\/rarediseases.info.nih.gov\/diseases\/8173\/achondroplasia#:~:text=Achondroplasia%20is%20a%20disorder%20of,small%20fingers%2C%20and%20normal%20intelligence<\/i> (accessd February 8, 2023)."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Baujat G, Legeai-Mallet L, Finidori G, Cormier-Daire V, Le Merrer M. Achondroplasia. Best Prac &amp; Res Clin Rheum. 2008; 22:3-18.","DOI":"10.1016\/j.berh.2007.12.008"},{"key":"4","unstructured":"4. MedlinePlus. FGFR3 gene. <i>https:\/\/medlineplus.gov\/genetics\/gene\/fgfr3\/#conditions<\/i> (accessd February 27, 2023)."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Horton WA, Hall JG, Hecht JT. Achondroplasia. Lancet. 2007; 370:162-172.","DOI":"10.1016\/S0140-6736(07)61090-3"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Chan ML, Qi Y, Larimore K, <i>et al<\/i>. Pharmacokinetics and exposure\u2013response of vosoritide in children with achondroplasia. Clin Pharmacokinet. 2022; 61:263-280.","DOI":"10.1007\/s40262-021-01059-1"},{"key":"7","unstructured":"7. European Union. EU research on rare diseases. <i>https:\/\/ec.europa.eu\/info\/research-and-innovation\/research-area\/health-research-and-innovation\/rare-diseases_en#:~:text=EU%20research%20on%20rare%20diseases,million%20people%20in%20the%20EU<\/i> (accessd February 10, 2023)."},{"key":"8","unstructured":"8. European Medicines Agency. Orphan designation: Overview. <i>https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/orphan-designation-overview#:~:text=The%20European%20Medicines%20Agency%20(EMA,of%20incentives%20in%20the%20EU<\/i> (accessd February 13, 2023)."},{"key":"9","unstructured":"9. European Medicines Agency. EMA&apos;s role in orphan designation. <i>https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/orphan-designation-overview#ema&apos;s-role-in-orphan-designation--section<\/i> (accessd February 19, 2023)."},{"key":"10","unstructured":"10. European Medicines Agency. Orphan incentives. <i>https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/orphan-designation\/orphan-incentives <\/i>(accessd February 21, 2023)."},{"key":"11","unstructured":"11. United States Food and Drug Administration. Rare Diseases at FDA. <i>https:\/\/www.fda.gov\/patients\/rare-diseases-fda<\/i> (accessd February 1, 2023)."},{"key":"12","unstructured":"12. United States Food and Drug Administration. FDA awards 11 grants to clinical trials to develop new medical products for rare disease treatments. <i>https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-awards-11-grants-clinical-trials-develop-new-medical-products-rare-disease-treatments<\/i> (accessd February 2, 2023)."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Rajagopal K. Applications of artificial intelligence in drug design, discovery and development. J Appl Pharm Sci. 2023; 13:i-ii.","DOI":"10.7324\/JAPS.2023.9.1ed"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Del Pozo A, Barker-Haliski M. Cannabidiol reveals a disruptive strategy for 21st century epilepsy drug discovery. Exp Neurol. 2023; 360:114288.","DOI":"10.1016\/j.expneurol.2022.114288"},{"key":"15","unstructured":"15. National Organization for Rare Disorders. Achondroplasia. <i>https:\/\/rarediseases.org\/rare-diseases\/achondroplasia\/ <\/i>(accessd February 4, 2023)."},{"key":"16","unstructured":"16. United States Food and Drug Administration. Zika Virus Response Updates from FDA. <i>https:\/\/www.fda.gov\/emergency-preparedness-and-response\/mcm-issues\/zika-virus-response-updates-fda<\/i> (accessd December 24, 2022)."},{"key":"17","unstructured":"17. United States Food and Drug Administration. Accelerated Approval. <i>https:\/\/www.fda.gov\/patients\/fast-track-breakthrough-therapy-accelerated-approval-priority-review\/accelerated-approval<\/i> (accessd Febuary 7, 2023)."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Duggan S. Vosoritide: First approval. Drugs. 2021; 81:2057-2062.","DOI":"10.1007\/s40265-021-01623-w"},{"key":"19","unstructured":"19. European Medicines Agency. CHMP assessment report. <i>https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/voxzogo-epar-public-assessment-report_en.pdf <\/i>(accessd June 3, 2023)."},{"key":"20","unstructured":"20. Irving M, Hoover-Fong J, Bacino C, Charrow J, Cormier-Daire V, Dickson P, Harmatz P, Labed AH, Jayaram K, Jeha G, Day J, Larimore K , Phillips J, Savarirayan R. Vosoritide for children with achondroplasia: A 30 month update from an ongoing phase 2 clinical trial. ESPE Abst. 2018; 89."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Savarirayan R, Tofts L, Irving M, <i>et al<\/i>. Persistent and stable growth promoting effects of vosoritide in children with achondroplasia for up to 2 years: Results from the ongoing phase 3 extension Study. J Endocr Soc. 2021; 5:A670-A671.","DOI":"10.1210\/jendso\/bvab048.1368"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Hussain RM, McIntosh SJ, Lawson J, Kenny RA. Fludrocortisone in the treatment of hypotensive disorders in the elderly. Heart. 1996; 76:507-509.","DOI":"10.1136\/hrt.76.6.507"}],"container-title":["Intractable &amp; Rare Diseases Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/12\/4\/12_2023.01055\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T05:07:09Z","timestamp":1701493629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/12\/4\/12_2023.01055\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,30]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.5582\/irdr.2023.01055","relation":{},"ISSN":["2186-361X","2186-3644"],"issn-type":[{"value":"2186-361X","type":"electronic"},{"value":"2186-3644","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,30]]},"article-number":"2023.01055"}}